Eterna Therapeutics Inc. (NASDAQ: ERNA) Stock Information | RedChip
Image

ASK REDCHAT® ANYTHING ABOUT ETERNA THERAPEUTICS INC.

Eterna Therapeutics Inc. (NASDAQ: ERNA)
Listen to this Section


$0.36
-0.0056 ( -2.17% ) 401.8K

Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.

Market Data


Open $0.36
Previous Close $0.36
Volume 401.8K
Market Cap $17.89M
Day Range $0.34 - $0.37
52 Week Range $0.22 - $2.63
Shares Outstanding 51.37M
Change % -2.17%
Net Change ▼ -0.0056
Insider Ownership 0.03%
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology: Pharmaceutical Preparations
IPO Year 2021
Country United States

Insider Ownership Transactions

Total Amount Purchased: 3,972,705.00

Date Type Amount Purchased Purchaser
2024-11-05 Buy 261756.00 Cherington Charles
2024-06-25 Sale -437.00 Gurrola Sandra M
2024-04-29 Sale -88946.00 Cicala Peter
2024-04-29 Sale -80000.00 Gurrola Sandra M
2024-04-29 Sale -124525.00 Bristol James Arthur
2024-01-03 Sale -1685218.00 Luther Sanjeev
2024-01-03 Sale -168521.00 Clarke Dorothy J
2023-12-20 Buy 3125976.00 Cherington Charles
2023-12-18 Buy 424928.00 Freebird Partners LP
2023-08-25 Buy 2307692.00 Cherington Charles

Institutional Ownership

Total Market Value $ 0.00

Symbol Issuer Name Market Value ↓ Share Quantity
No records found.

SEC Fillings


Form Type Description Pages Date
upload Comment letters 2 Nov 13, 2024
corresp Comment letters 1 Nov 13, 2024
10-q Quarterly Reports 80 Nov 12, 2024
s-1 Registration statements 7 Nov 05, 2024
4 Insider transactions 1 Nov 05, 2024
8-k 8K-related 16 Oct 29, 2024
ars Annual reports 1 Oct 16, 2024
def Proxies and info statements 6 Oct 07, 2024
pre Proxies and info statements 6 Sep 27, 2024
8-k 8K-related 13 Sep 27, 2024

Latest News


× Before browsing our site, please accept our cookies policy